Serum level of CCL2 predicts outcome of patients with pancreatic cancer
| Journal | Volume 83 - 2020 |
| Issue | Fasc.2 - Original articles |
| Author(s) | L. Feng 1 2, Q. Qi 1 2, P. Wang 1 2, H. Chen 1 2, Z. Chen 1 2, Z. Meng 1 2, L. Liu 1 2 |
| Full article |
 PAGES 295-299 VIEW FREE PDF |
|
Affiliations: (1) Departments of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
(2) Department of Oncology, Shanghai Medical College, Shanghai 200032, China. |
|
Background: Pancreatic cancer is one of the most deadly cancers worldwide with a five-year survival rate of less than 5%. Chronic pancreatitis showed increased risk to develop pancreatic cancer, in which chronic inflammation of the pancreas may play a critical role. Cytokines play an indispensable role in inflammatory reaction and tumorigenesis. The purpose of this study was to determine whether cytokines were associated with survival and poor prognosis of pancreatic cancer. Methods: In this study, we examined levels of some important cytokines in the serum of 68 patients with pancreatic cancer, including CCL2, CCL17, CXCL-1, CXCL-5, G-CSF, GM-CSF, TGF-β and IFN-γ. Results: We found that high level of serum CCL2 was strongly associated with poor survival and prognosis, but no significant association with other clinicopathological features, including gender, age, location and TNM staging. For other cytokines, no significant correlation with poor survival and prognosis was found. Conclusion: Our results suggest that serum level of CCL2 may serve as a potential marker for predicting the outcome of patients with pancreatic cancer. Keywords: pancreatic cancer, cytokines, CCL2, prediction marker. |
| The authors declare that they have no conflict of interest. |
|
© Acta Gastro-Enterologica Belgica. PMID 32603049 |
